Full Breakdown
Novo Nordisk Sues Hims & Hers Over Compounded Obesity Drugs
2/10/2026, 3:13:00 PM
Legal Action and Allegations
Novo Nordisk, a Danish pharmaceutical company, has filed a lawsuit against Hims & Hers Health Inc., alleging that the telehealth provider infringed on its patents by selling unapproved compounded versions of its weight-loss drugs, Wegovy and Ozempic. The lawsuit, filed in the U.S. District Court in Delaware on February 9, 2026, seeks a permanent ban on Hims' sales of these compounded drugs and demands damages for patent infringement. Novo claims that Hims is mass marketing these unapproved products, which evade the rigorous FDA review process, thereby endangering patient safety.
Background of the Dispute
The conflict escalated when Hims announced plans to sell a compounded version of Wegovy at an introductory price of $49 per month, significantly undercutting Novo's pricing of $149 for the same medication. This announcement came shortly after the FDA declared that the shortage of semaglutide, the active ingredient in Wegovy, was over, allowing Novo to ramp up production. Hims had previously justified its compounded offerings by claiming they were personalized, despite the fact that semaglutide is protected by U.S. patents until 2032.
Responses from Both Companies
John Kuckelman, Novo's general counsel, criticized Hims' actions, stating, "This is a complete sham... their medicines are untested, and they're putting patients at risk." In contrast, Hims characterized the lawsuit as a "blatant attack" on millions of Americans who rely on compounded medications for personalized care. The company accused Novo of "weaponizing the U.S. judicial system to limit consumer choice."
Regulatory Scrutiny and Market Impact
The FDA has also taken a firm stance against Hims, announcing plans to restrict the use of GLP-1 ingredients in compounded drugs marketed by the company. The agency's actions follow concerns over the quality and safety of compounded medications, which are not subject to the same rigorous testing as FDA-approved drugs. Following the announcement of the lawsuit, Hims' stock plummeted by over 16%, while Novo's shares rose by approximately 3%.
Criticism and Opposition
Critics of Novo's lawsuit argue that it undermines the practice of compounding, which can provide essential medications tailored to individual patient needs. Hims has emphasized its commitment to providing affordable and personalized healthcare, asserting that its compounded drugs are legal under current regulations. However, Novo contends that the mass compounding practices employed by Hims are unlawful and pose significant risks to patient health.
What's Next?
The legal battle between Novo Nordisk and Hims & Hers is poised to unfold in the coming months, with potential implications for the broader market for compounded GLP-1 drugs. As the FDA intensifies its scrutiny of compounded medications, the future of Hims' offerings remains uncertain. The outcome of this lawsuit could significantly impact both companies and the availability of compounded obesity treatments in the U.S. market.
Verbatim Quotes
- “This is a complete sham, and it has been a sham since the shortage ended,” — John Kuckelman, General Counsel, Novo Nordisk
- “Novo Nordisk’s lawsuit is a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care.” — Hims & Hers spokesperson
- “I would just say we do want an end to mass compounding, to unlawful mass compounding.” — John Kuckelman, General Counsel, Novo Nordisk
This ongoing legal dispute highlights the tensions between pharmaceutical companies and telehealth providers in the rapidly evolving landscape of obesity treatments.
